6 results on '"Zethoven, M"'
Search Results
2. Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment.
- Author
-
Zethoven M, Martelotto L, Pattison A, Bowen B, Balachander S, Flynn A, Rossello FJ, Hogg A, Miller JA, Frysak Z, Grimmond S, Fishbein L, Tischler AS, Gill AJ, Hicks RJ, Dahia PLM, Clifton-Bligh R, Pacak K, and Tothill RW
- Subjects
- Humans, Tumor Microenvironment genetics, Succinate Dehydrogenase genetics, Pheochromocytoma genetics, Paraganglioma genetics, Paraganglioma pathology, Adrenal Gland Neoplasms genetics, Adrenal Gland Neoplasms pathology
- Abstract
Pheochromocytomas (PC) and paragangliomas (PG) are rare neuroendocrine tumors associated with autonomic nerves. Here we use single-nuclei RNA-seq and bulk-tissue gene-expression data to characterize the cellular composition of PCPG and normal adrenal tissues, refine tumor gene-expression subtypes and make clinical and genotypic associations. We confirm seven PCPG gene-expression subtypes with significant genotype and clinical associations. Tumors with mutations in VHL, SDH-encoding genes (SDHx) or MAML3-fusions are characterized by hypoxia-inducible factor signaling and neoangiogenesis. PCPG have few infiltrating lymphocytes but abundant macrophages. While neoplastic cells transcriptionally resemble mature chromaffin cells, early chromaffin and neuroblast markers are also features of some PCPG subtypes. The gene-expression profile of metastatic SDHx-related PCPG indicates these tumors have elevated cellular proliferation and a lower number of non-neoplastic Schwann-cell-like cells, while GPR139 is a potential theranostic target. Our findings therefore clarify the diverse transcriptional programs and cellular composition of PCPG and identify biomarkers of potential clinical significance., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
3. MAIT cells regulate NK cell-mediated tumor immunity.
- Author
-
Petley EV, Koay HF, Henderson MA, Sek K, Todd KL, Keam SP, Lai J, House IG, Li J, Zethoven M, Chen AXY, Oliver AJ, Michie J, Freeman AJ, Giuffrida L, Chan JD, Pizzolla A, Mak JYW, McCulloch TR, Souza-Fonseca-Guimaraes F, Kearney CJ, Millen R, Ramsay RG, Huntington ND, McCluskey J, Oliaro J, Fairlie DP, Neeson PJ, Godfrey DI, Beavis PA, and Darcy PK
- Subjects
- Animals, Antineoplastic Agents, Cell Line, Tumor, Cytokines, Histocompatibility Antigens Class I genetics, Humans, Immunity, Mice, Mice, Inbred C57BL, Mice, Knockout, Minor Histocompatibility Antigens genetics, Neoplasm Metastasis, Neoplasms pathology, Immunity, Cellular, Killer Cells, Natural immunology, Mucosal-Associated Invariant T Cells immunology, Neoplasms immunology
- Abstract
The function of MR1-restricted mucosal-associated invariant T (MAIT) cells in tumor immunity is unclear. Here we show that MAIT cell-deficient mice have enhanced NK cell-dependent control of metastatic B16F10 tumor growth relative to control mice. Analyses of this interplay in human tumor samples reveal that high expression of a MAIT cell gene signature negatively impacts the prognostic significance of NK cells. Paradoxically, pre-pulsing tumors with MAIT cell antigens, or activating MAIT cells in vivo, enhances anti-tumor immunity in B16F10 and E0771 mouse tumor models, including in the context of established metastasis. These effects are associated with enhanced NK cell responses and increased expression of both IFN-γ-dependent and inflammatory genes in NK cells. Importantly, activated human MAIT cells also promote the function of NK cells isolated from patient tumor samples. Our results thus describe an activation-dependent, MAIT cell-mediated regulation of NK cells, and suggest a potential therapeutic avenue for cancer treatment., (© 2021. Crown.)
- Published
- 2021
- Full Text
- View/download PDF
4. Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes.
- Author
-
Subramanian DN, Zethoven M, McInerny S, Morgan JA, Rowley SM, Lee JEA, Li N, Gorringe KL, James PA, and Campbell IG
- Subjects
- Adult, Aged, Aged, 80 and over, Cohort Studies, Cystadenocarcinoma, Serous pathology, Female, Humans, Loss of Function Mutation, Middle Aged, Ovarian Neoplasms pathology, Exome Sequencing, Young Adult, Cystadenocarcinoma, Serous genetics, Exome, Genetic Heterogeneity, Genetic Predisposition to Disease, Ovarian Neoplasms genetics
- Abstract
High-grade serous ovarian carcinoma (HGSOC) has a significant hereditary component, approximately half of which cannot be explained by known genes. To discover genes, we analyse germline exome sequencing data from 516 BRCA1/2-negative women with HGSOC, focusing on genes enriched with rare, protein-coding loss-of-function (LoF) variants. Overall, there is a significant enrichment of rare protein-coding LoF variants in the cases (p < 0.0001, chi-squared test). Only thirty-four (6.6%) have a pathogenic variant in a known or proposed predisposition gene. Few genes have LoF mutations in more than four individuals and the majority are detected in one individual only. Forty-three highly-ranked genes are identified with three or more LoF variants that are enriched by three-fold or more compared to GnomAD. These genes represent diverse functional pathways with relatively few involved in DNA repair, suggesting that much of the remaining heritability is explained by previously under-explored genes and pathways.
- Published
- 2020
- Full Text
- View/download PDF
5. The molecular origin and taxonomy of mucinous ovarian carcinoma.
- Author
-
Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Anglesio MS, Au-Yeung G, Böhm M, Bowtell DDL, Brand A, Chenevix-Trench G, Christie M, Chiew YE, Churchman M, DeFazio A, Demeo R, Dudley R, Fairweather N, Fedele CG, Fereday S, Fox SB, Gilks CB, Gourley C, Hacker NF, Hadley AM, Hendley J, Ho GY, Hughes S, Hunstman DG, Hunter SM, Jobling TW, Kalli KR, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Mes-Masson AM, Mileshkin L, Provencher DM, Pyman J, Rahimi K, Rowley SM, Salazar C, Samimi G, Saunders H, Semple T, Sharma R, Sharpe AJ, Stephens AN, Thio N, Torres MC, Traficante N, Xing Z, Zethoven M, Antill YC, Scott CL, Campbell IG, and Gorringe KL
- Subjects
- Adenocarcinoma, Mucinous classification, Adenocarcinoma, Mucinous metabolism, Carcinoma, Ovarian Epithelial classification, Carcinoma, Ovarian Epithelial metabolism, Cohort Studies, Female, Gene Expression Regulation, Neoplastic, Humans, Mutation, Ovarian Neoplasms classification, Ovarian Neoplasms metabolism, Sequence Analysis, DNA methods, Survival Analysis, Adenocarcinoma, Mucinous genetics, Carcinoma, Ovarian Epithelial genetics, Gene Expression Profiling methods, Ovarian Neoplasms genetics
- Abstract
Mucinous ovarian carcinoma (MOC) is a unique subtype of ovarian cancer with an uncertain etiology, including whether it genuinely arises at the ovary or is metastatic disease from other organs. In addition, the molecular drivers of invasive progression, high-grade and metastatic disease are poorly defined. We perform genetic analysis of MOC across all histological grades, including benign and borderline mucinous ovarian tumors, and compare these to tumors from other potential extra-ovarian sites of origin. Here we show that MOC is distinct from tumors from other sites and supports a progressive model of evolution from borderline precursors to high-grade invasive MOC. Key drivers of progression identified are TP53 mutation and copy number aberrations, including a notable amplicon on 9p13. High copy number aberration burden is associated with worse prognosis in MOC. Our data conclusively demonstrate that MOC arise from benign and borderline precursors at the ovary and are not extra-ovarian metastases.
- Published
- 2019
- Full Text
- View/download PDF
6. Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis.
- Author
-
Kelly MJ, So J, Rogers AJ, Gregory G, Li J, Zethoven M, Gearhart MD, Bardwell VJ, Johnstone RW, Vervoort SJ, and Kats LM
- Subjects
- Animals, Cell Proliferation, Gene Expression Regulation, Leukemic, Hematopoietic Stem Cells metabolism, Histones metabolism, Homeodomain Proteins metabolism, Leukemia genetics, Lysine metabolism, Mice, Inbred C57BL, Mutation genetics, Polycomb Repressive Complex 1 metabolism, Proto-Oncogene Proteins p21(ras) metabolism, Repressor Proteins genetics, Repressor Proteins metabolism, Transcription Factors metabolism, Transcription, Genetic, Ubiquitination, Carcinogenesis metabolism, Carcinogenesis pathology, Cell Differentiation, Leukemia pathology, Myeloid Cells pathology, Repressor Proteins deficiency
- Abstract
The BCL6 Corepressor (BCOR) is a component of a variant Polycomb repressive complex 1 (PRC1) that is essential for normal development. Recurrent mutations in the BCOR gene have been identified in acute myeloid leukaemia and myelodysplastic syndrome among other cancers; however, its function remains poorly understood. Here we examine the role of BCOR in haematopoiesis in vivo using a conditional mouse model that mimics the mutations observed in haematological malignancies. Inactivation of Bcor in haematopoietic stem cells (HSCs) results in expansion of myeloid progenitors and co-operates with oncogenic Kras
G12D in the initiation of an aggressive and fully transplantable acute leukaemia. Gene expression analysis and chromatin immunoprecipitation sequencing reveals differential regulation of a subset of PRC1-target genes including HSC-associated transcription factors such as Hoxa7/9. This study provides mechanistic understanding of how BCOR regulates cell fate decisions and how loss of function contributes to the development of leukaemia.- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.